Skip to main content
Log in

Phase I trial of intravenous carboplatin added to oral etoposide and oral cyclophosphamide for stage IV non-small cell lung cancer

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

The combination of oral etoposide and oral cyclophosphamide is an active and easily administered outpatient regimen for non-small cell lung cancer with leukopenia as the most common severe toxicity. To maintain ease of outpatient administration and to take advantage of a differing dose-limiting toxicity, we attempted to add escalating doses of intravenous carboplatin to full-dose oral etoposide and oral cyclophosphamide for chemotherapy-naive patients with Stage IV non-small cell lung cancer. The first 4 patients received etoposide and cyclophosphamide (each at 50 mg PO BID Days 1–12 every 28 days) with intravenous carboplatin on Day 1 at a dose calculated by the Calvert formula to achieve AUC 4. With this regimen dose-limiting toxicity (2 patients with Grade 4 leukopenia/granulocytopenia) was noted. An additional 3 patients therefore received etoposide and cyclophosphamide at a 25% reduced dose (each at 50 mg PO BID Days 1–9 every 28 days) with intravenous carboplatin on Day 1 at a dose calculated to achieve AUC 4. Dose-limiting toxicity (2 patients with Grade 4 leukopenia/granulocytopenia) was again noted. One patient achieved a partial response maintained for 6 months. However potentiation of leukopenia/granulocytopenia by carboplatin prevents full-dose use of either cyclophosphamide and etoposide or of carboplatin in this regimen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF, Hill DP: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer report of a Canadian multicentre randomized trial. J Clin Oncol 6:633–641, 1988

    PubMed  Google Scholar 

  2. Grunberg SM, Crowley J, Livingston R, Gill I, Williamson SK, O'Rourke T, Braun T, Marshall ME, Weick JK, Balcerzak SP, Martine RL: Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 11:1598–1601, 1993

    PubMed  Google Scholar 

  3. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756, 1989

    PubMed  Google Scholar 

  4. Miller AA, Niell HB, Griffin JP: Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer. Lung Cancer 12:59–65, 1995

    PubMed  Google Scholar 

  5. Johnson DH, DeVore R, Greco FA, Walls J, Thomas M, Hande KR, Hainsworth JD: Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial. Semin Oncol 19 (1 suppl 2):50–56, 1992

    PubMed  Google Scholar 

  6. Shepherd FA, Evans WK, Goss PE, Latreille J, Logan D, Maroun J, Stewart D, Warner E, Paul K: Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer. Semin Oncol 19 (1 suppl 2):54–58, 1992

    Google Scholar 

  7. Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD, Johnson DH: Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 13:1615–1622, 1995

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grunberg, S.M., Valentine, J., Zackon, I. et al. Phase I trial of intravenous carboplatin added to oral etoposide and oral cyclophosphamide for stage IV non-small cell lung cancer. Invest New Drugs 13, 333–335 (1995). https://doi.org/10.1007/BF00873140

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00873140

Key words

Navigation